Alkermes plc (ALKS) fair value analysis
Nasdaq · Updated 2026-10-19
ALKS price how computed
Forward Fair Value verdict
OvervaluedALKS is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $41.22
- Sector
- Healthcare
- 12-month range
- $27.20–$55.22
- Market cap
- $6.92B
- From 52-week high
- -25.4%
- Shares outstanding
- 168M
- Rank in Healthcare by discount to fair value
- #91 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Alkermes plc is a biopharmaceutical company that develops and commercializes medicines for the treatment of central nervous system disorders, including schizophrenia, bipolar disorder, and opioid addiction. The company operates globally with operations in the United States, Ireland, and other international markets.
ALKS currently ranks #91 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $6.92B
- P/E (trailing)
- 22x
- Revenue (TTM)
- $1.67B
- Net margin
- 4.0%
- EPS (TTM)
- $1.84
- Gross margin
- 80.2%
- Debt / equity
- 0.87
- Revenue growth (3-yr avg)
- 10.1%
- Shares outstanding
- 168M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 38 · neutral
- 50-day average
- $45.08
- 200-day average
- $39.72
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-27
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1400.0%)
2026-03 ▲ beat (+1050.0%)
2025-12 ▼ miss (-29.3%)
2025-09 ▲ beat (+66.7%)
2025-06 ▲ beat (+70.0%)
2025-03 ▲ beat (+20.8%)
2024-12 ▲ beat (+38.2%)
2024-09 ▲ beat (+2.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 4 hold · 1 sell (19 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $56.2
- Target vs last price
- +36.3%
What our data shows for ALKS
- Our model validated 16 trailing price-to-earnings windows for ALKS, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $27.20–$55.22.
- The 14-day relative strength index sits at a neutral 38.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ALKS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ALKS news
TickrTrends' derived news-sentiment signal for ALKS is currently leaning positive, computed from recent coverage.
- A Look at Alkermes PLC (ALKS) After 4.2% Gain -- GF Value $32.92 vs Price $42.97 (gurufocus.com, 2026-10-19)
TickrTrends take: Alkermes trades at a significant premium to its estimated intrinsic value, with the current market price substantially above the GF Value assessment. For a valuation-focused investor, the gap between these figures underscores TickrTrends' overvalued designation and suggests monitoring whether the stock price moves closer to fundamental value or if the company's underlying business performance justifies the current premium. In the Healthcare sector, this valuation gap warrants observation of upcoming earnings reports and clinical trial results that could either support the higher valuation or create pressure toward the lower estimate. - Truist Securities Reinstates Alkermes (ALKS) Coverage with Buy Rating and $55 Price Target (gurufocus.com, 2026-10-16)
TickrTrends take: Truist Securities has reinstated coverage of Alkermes with a Buy rating and a $55 price target, suggesting confidence in the company's prospects within the Healthcare sector. This analyst action contrasts with TickrTrends' current assessment that the stock is overvalued, creating a divergence between institutional expectations and the valuation metrics that inform algorithmic analysis. Investors focused on valuation should monitor whether fundamental developments or market conditions shift to reconcile this gap between the analyst's target price and the current overvalued designation. - Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works? (insidermonkey.com, 2026-09-26)
TickrTrends take: Alkermes reported early results for an ADHD drug candidate, with the critical question being whether a larger trial will validate efficacy at scale. Given TickrTrends' current overvalued assessment, investors should monitor whether this development provides genuine pipeline value or whether market enthusiasm has already priced in optimistic outcomes. The Healthcare sector context suggests that clinical execution risk and trial success rates warrant careful scrutiny before any valuation re-rating could be justified.
More ALKS news
- Alkermes PLC (ALKS) Shares Fall 3.2% -- GF Value Says Still Overvalued (gurufocus.com, 2026-09-24)
- ALKS Reinstated by Goldman Sachs -- Rating Set to Neutral (gurufocus.com, 2026-09-24)
What people are saying
Follow the ALKS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ALKS moved from an overvalued status this week as its quality grade declined from A to B, while its relative strength index shifted out of oversold territory into the neutral zone. The company operates in the Healthcare sector and the combination of the lower quality assessment and improved momentum reading reflects changing technical conditions in the stock's recent trading activity.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — ALKS has moved into oversold territory on the relative strength index this week, shifting from a neutral zone in the previous week's assessment. Despite the technical indicator showing oversold conditions, TickrTrends' derived valuation metrics continue to reflect an overvalued position for the healthcare sector company.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ALKS stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ALKS is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is ALKS's TickrTrends verdict?
ALKS's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does ALKS compare to other Healthcare stocks?
ALKS ranks #91 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ALKS overbought or oversold?
ALKS's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ALKS report earnings next?
ALKS's next earnings report is scheduled for 2026-10-27, per the published earnings calendar.
Does ALKS usually beat earnings estimates?
Over its last 8 reported quarters ALKS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ALKS?
Of 19 analysts covering ALKS, 14 rate it a buy, 4 a hold and 1 a sell - buy-leaning, with a consensus price target of $56.2 (+36.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ALKS vs ATEC · ALKS vs CDNA · ALKS vs CRL · ALKS vs CSTL · ALKS vs HUM